Navigation Links
MiMedx Announces Record Third Quarter Results
Date:10/30/2013

MARIETTA, Ga., Oct. 30, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended September 30, 2013.

Highlights of third quarter of 2013 results include:

  • Revenue exceeds high end of guidance (8th consecutive quarter of meeting or exceeding upper end of guidance)
  • Revenue increased more than 100% over third quarter of 2012
  • Nine-month revenue increased nearly 150% over same period of 2012
  • 7th consecutive quarter of positive Adjusted EBITDA
  • Quarterly Cash Flow from Operations Positive for the First time in Company History
  • Company reiterates increased lower end of 2013 full year revenue guidance
  • Third Quarter 2013 Results
    The Company recorded record revenue for the quarter ended September 30, 2013, with revenue of $16.1 million, an increase of more than 100% over third quarter of 2012 revenue of $8.0 million. The Company's third quarter gross margins were 87% as compared to gross margins of 82% in the third quarter of last year.  Earnings before interest, taxes, depreciation, amortization and share based compensation (Adjusted EBITDA*) for the third quarter of 2013 were $1.9 million, a $1.1 million  or  156% improvement, as compared to the Adjusted EBITDA of $726,000 for the third quarter of 2012. The Net Loss for the third quarter of 2013 was $307,000 as compared to net loss of $4.2 million in the prior year third quarter. The prior year Net Loss included a $1.8 million Intangible Asset impairment charge and a $1.3 million charge related to the fair value adjustment of the earn-out liability related to the acquisition of Surgical Biologics. 

    <
    '/>"/>
    SOURCE MiMedx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. MiMedx Reports On Meeting With FDA
    2. MiMedx Responds To Misleading And Inaccurate Media Reports
    3. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
    4. MiMedx To Present At 33rd Annual Canaccord Genuity Growth Conference
    5. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
    6. MiMedx Announces Record Second Quarter Results
    7. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
    8. MiMedx To Exceed High End Of Second Quarter Guidance
    9. MiMedx to Ring NASDAQ Stock Market Opening Bell
    10. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
    11. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/30/2015)... March 30, 2015    Intrexon Corporation ... biology, and Merck Serono, the biopharmaceutical business of ... today announced an exclusive strategic collaboration and license ... T-cell (CAR-T) cancer therapies. This collaboration advances Merck ... that modulate the immune system,s natural ability to ...
    (Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
    (Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
    (Date:3/27/2015)... 2015 The consumption of compound fertilizers ... recession and high prices in 2008. However, the situation ... keeps on gaining momentum now. , To date, the ... than 100,000 thousand tonnes. No considerable growth was registered ... capacity rocketed during 2012-2013, registering 11% growth as against ...
    Breaking Biology Technology:Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3
    ... June 16 Naviscan PET Systems(R), a company,specializing ... the Society of Nuclear Medicine,s Annual Meeting, new ... cancer management. The PEM,Flex(TM) Solo II is a ... for the breast application known as positron,emission mammography, ...
    ... Medullary Thyroid Cancer Planned to Initiate This Summer, ... Inc. (Nasdaq: EXEL ) announced today that ... (FDA) have reached agreement on the phase 3,registration ... targeting,MET, RET, and VEGFR2, via the Special Protocol ...
    ... NDC #58177-320-04 & 58177-330-04 ... Lot Numbers listed below, ST. ... recalled specific additional lots of morphine,sulfate 60 mg extended release tablets, ... a precaution, due to the,possible presence of oversized tablets. Oversized tablets ...
    Cached Biology Technology:Naviscan's PEM Flex(TM) Detects Smallest Cancers Better Compared to MRI in an Independent Study 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4
    (Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
    (Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
    (Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
    Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
    ... Brine water that flows back from gas wells in ... times more salty than seawater, with high contents of ... consistent with brines formed during the Paleozoic era, a ... Penn State,s Department of Geosciences found. The study indicates ...
    ... of Energy,s National Renewable Energy Laboratory (NREL) will partner ... a five-year, $7 million effort to economically produce drop-in ... the federal laboratory announced today. The work will ... (CRADA) between NREL and Johnson Matthey. "It,s a ...
    ... The Hass Avocado Board (HAB) is supporting ... benefits of consuming fresh avocados to human health ... investigate the relationship between avocado consumption and risk ... in weight management and diabetes, and avocados, ability ...
    Cached Biology News:Analysis of Marcellus flowback finds high levels of ancient brines 2NREL and Johnson Matthey announce 5-year collaboration on biofuels 2Hass Avocado Board study published in Food & Function journal 2
    ... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
    ... standard is a new tuning and calibration ... mass spectrometry. Accumix is a lyophilized ... coverage for both tuning and calibration of ... and Fourier transform mass spectrometers. Direct ...
    Determine relative degree of protein binding to phosphoinositides...
    ... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
    Biology Products: